Search
Frovatriptan
go.drugbank.com/drugs/DB00998ApprovedFrovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation.
Dexlansoprazole
go.drugbank.com/drugs/DB05351Approved[A19566, A19568, A178084, A174244] Dexlansoprazole inhibits the final step in gastric acid production by blocking the (H+, K+)-ATPase enzyme.[L48827]
Cevimeline
go.drugbank.com/drugs/DB00185ApprovedIt is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome.
Mercaptopurine
go.drugbank.com/drugs/DB01033ApprovedInvestigationalIt interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Indium In-111 oxyquinoline
go.drugbank.com/drugs/DB09473ApprovedIndium-111 decays by isomeric transition and electron capture to cadmium-111, emitting a gamma ray that can be detected with a gamma ray camera.
Tianeptine
go.drugbank.com/drugs/DB09289InvestigationalAsia (including Singapore) and Latin America as “Stablon” and “Tatinol” but it is not available in Australia, Canada, New Zealand, the U.K. or the U.S. … Tianeptine was discovered and patented by The French Society of Medical Research in the 1960s [L2946].
Diloxanide
go.drugbank.com/drugs/DB08792ExperimentalAlthough it is not currently approved for use in the United States, it was approved by a CDC study in the treatment of 4,371 cases of Entamoeba histolytica from 1977 to 1990.
Benzyl benzoate
go.drugbank.com/drugs/DB00676ApprovedScabies is a skin infection caused by the mite sarcoptes scabiei. It is characterised by severe itching (particularly at night), red spots, and may lead to a secondary infection.
Fulvestrant
go.drugbank.com/drugs/DB00947ApprovedInvestigationalIt is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.
Lapatinib
go.drugbank.com/drugs/DB01259ApprovedInvestigationalLapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. … It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine.